Cytotoxicity of combinations of IFN-β and chemotherapeutic drugs

Journal of Interferon and Cytokine Research

Volumn 22, Issue 8, 2002, Pages 873-880

  Brickelmaier, Margot ^a   Carmillo, Amie ^a   Goelz, Susan ^a   Barsoum, James ^a   Qin, Xiao Qiang ^a,b  

^a BIOGEN   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA INTERFERON; CISPLATIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PLATINUM;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL DEATH; CELL DIVISION; CISPLATIN; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-BETA; LUNG NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0036407329     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999002760274881     Document Type: Article

References (33)

1. Lengyel P. (1982). Biochemistry of interferons and their actions. Annu. Rev. Biochem. 51, 251-282.
2. Belardelli, F., and Gresser, I. (1996). The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17, 369-372.
3. Sen, G.C. (2001). Viruses and interferons. Annu. Rev. Microbiol. 55, 255-281.
4. 1 arrest in the inhibition of tumor cell growth by interferon. Proc. Natl. Acad. Sci. USA 77, 1471-1475.
5. Fuse, A., and Kuwata, T. (1997). Inhibition of DNA synthesis of synchronized Rsa cells by human leukocyte interferon. J. Natl. Cancer Inst. 58, 891-896.
6. Kimchi, A. (1992). Cytokine triggered molecular pathways that control cell cycle arrest. J. Cell. Biochem. 50, 1-9.
7. Oberg, K. (1992). The action of interferon alpha on human carcinoid tumors. Semin. Cancer Biol. 3, 35-41.
8. Qin, X.-Q., Runkel, L., Deck, C., Dedios, C., and Barsoum, J. (1997). Interferon-β induces S phase accumulation selectively in human transformed cells. J. Interferon Cytokine Res. 17, 355-367.
9. Qin, X.-Q., Tao, N., Dergay, A., Moy, P., Fawell, S., Davis, A., Wilson, J.M., and Barsoum, J. (1998). Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA 95, 14411-14416.
10. Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., and Yagita, H. (1999). Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451-1460.
11. Tada, H., Maron, D.J., Choi, E.A., Barsoum, J., Lei, H., Xie, Q., Liu, W., Ellis, L., Moscioni, D., Tazelaar, J., Fawell, S., Qin, X., Propert, K.J., Davis, A., Fraker, D.L., Wilson, J.M., and Spitz, F.R. (2001). Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases. J. Clin. Invest. 108, 83-95.
12. Salmon, P., Le Cotonnec, J.Y., Galazka, A., Abdulahad, A., and Darragh, A. (1996). Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J. Interferon Cytokine Res. 16, 759-764.
13. Fierlbeck, G., Ulmer, A., Schreiner, T., Stroebel, W., Schiebel, U., and Brzoska, J. (1996). Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma. J. Interferon Cytokine Res. 16, 777-781.
14. Qin, X.-Q., Beckham, C., Brown, J.L., Lukashev, M., and Barsoum, J. (2001). Human and mouse IFN-β gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol. Ther. 4, 356-363.
15. Wadler, S., and Schwartz, E.L. (1990). Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 50, 3473-3486.
16. Hawkins, D.S., Demers, G.W., and Galloway, D.A. (1996). Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56, 892-898.
17. Haas-Kogan, D.A., Kogan, S.C., Levi, D., Dazin, P., T'Ang, A., Fung, Y.-K.T., and Israel, M.A. (1995). Inhibition of apoptosis by the retinoblastoma gene product. EMBO J. 14, 461-472.
18. American Cancer Society. (2001). Cancer Facts and Figures 2001. Atlanta: American Cancer Society.
19. Gouyer, V., Gazzeri, S., Bolon, I., Drevet, C., Brambilla, C., and Brambilla, E. (1998). Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am. J. Respir. Cell Mol. Biol. 18, 188-196.
20. Xu, H.J., Quinlan, D.C., Davidson, A.G., Hu, S.X., Summers, C.L., LI, J., and Benedict, W.F. (1994). Altered retinoblastoma protein expression and prognosis in early-stage nonsmall cell lung carcinoma. J. Natl. Cancer Inst. 86, 695-699.
21. Gazzeri, S., Gouyer, V., Vourc'h, C., Brambilla, C., and Brambilla, E. (1998). Mechanisms of p16INK4A inactivation in non-small cell lung cancers. Oncogene 16, 497-505.
22. Brambilla, E., Gazzeri, S., Moro, D., Lantuejoul, S., Veyrenc, S., and Brambilla, C. (1999). Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin. Cancer Res. 5, 243-250.
23. Joseph, B., Marchetti, P., Formstecher, P., Kroemer, G., Lewensohn, R., and Zhivotovsky, B. (2002). Mitochondrial dysfunction is an essential step for killing of nonsmall cell lung carcinomas resistant to conventional treatment. Oncogene 21, 65-77.
24. Lane, D.P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16.
25. Hartwell, L.H., and Kastan, M.B. (1994). Cell cycle control and cancer. Science 266, 1821-1828.
26. El-Deiry, W.S., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, J.M., Lin, D., Mercer, E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
27. Smith, M.L., Chen, I.T., Zhan, Q., Bae, I., Chen, C.Y., Gilmer, T.M., Kastan, M.B., O'Connor, P.M., and Fornace, A.J., Jr. (1994). Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266, 1376-1380.
28. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967.
29. Fan, S., El-Deiry, W.S., Bae, I., Freeman, J., Jondic, D., Bhatia, K., Fornace, A.J., Magrath, I., Kohn, K.W., and O'Connor, P.M. (1994). p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res. 54, 5824-5830.
30. Evan, G.I., and Littlewood, T.D. (1993). The role of c-myc in cell growth. Curr. Opin. Genet. Dev. 3, 44-49.
31. Heald, R., McLoughlin, M., and McKeon, F. (1993). Human Wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated cdc2 kinase. Cell 74, 463-474.
32. +, a gene encoding a protein kinase homolog. Cell 49, 559-567.
33. Elias, L., and Sandoval, J.M. (1989). Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem. Biophys. Res. Commun. 163, 867-874.